--- title: "AIM ImmunoTech (AIM) news: reverse split and delisting" url: "https://aibio.space/companies/aim-immunotech/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "AIM reverse split, delisting, going concern and offering news: AIM ImmunoTech prices $8.0 million unit offering as it works to fix equity shortfall." --- AIM AIM ImmunoTech Inc. AMEX · United States # AIM ImmunoTech (AIM) news AIM reverse split, delisting and going concern news Debt Financing · 2026-08-31 ## [AIM ImmunoTech satisfies Streeterville note in full through share exchanges](https://aibio.space/news/aim-immunotech-satisfies-streeterville-note-full-through-share/) AIM ImmunoTech converted approximately $1,224,341 of a February 16, 2024 promissory note held by Streeterville Capital, LLC into 5,065,840 shares, and the note was satisfied in full as of September 3, 2026. ## Latest AIM ImmunoTech news 1. 2026-06-15 Listings [AIM ImmunoTech regains NYSE American stockholders' equity compliance](https://aibio.space/news/aim-immunotech-regains-nyse-american-stockholders-equity-compliance/) The NYSE American said on June 12, 2026 that AIM had resolved its stockholders' equity deficiencies after a series of share sales and warrant exercises in May and June. 2. 2026-06-04 Company Updates [AIM ImmunoTech releases video segment on Ebola and Ampligen](https://aibio.space/news/aim-immunotech-releases-video-segment-ebola-ampligen/) The company said on June 4, 2026 that its virtual investor video discusses Ampligen's Ebola research, and that an updated Ebola-focused presentation is available on its website. 3. 2026-05-19 Debt Financing [AIM ImmunoTech pushes Streeterville note maturity to June 2027](https://aibio.space/news/aim-immunotech-pushes-streeterville-note-maturity-june-2027/) The note is now due June 30, 2027. The balance is about $1.68 million after the amendment and the extension fee. 4. 2026-05-14 Company Updates [AIM ImmunoTech posts KOL segment on Ampligen in pancreatic cancer](https://aibio.space/news/aim-immunotech-posts-kol-segment-ampligen-pancreatic-cancer/) The company said the on-demand segment features an Erasmus MC surgeon who discusses named patient program results and interim data from the ongoing Phase 2 trial. 5. 2026-05-07 Financings [AIM ImmunoTech arranges warrant inducement through Ladenburg Thalmann](https://aibio.space/news/aim-immunotech-arranges-warrant-inducement-through-ladenburg-thalmann/) Existing holders agreed to exercise warrants at $0.48 a share in exchange for new Class H warrants, with gross proceeds of approximately $4.20 million if all existing warrants are exercised. 6. 2026-04-10 Financings [AIM ImmunoTech amends at-the-market sales agreement with Maxim Group](https://aibio.space/news/aim-immunotech-amends-market-sales-agreement-maxim-group/) The amendment names Maxim Group LLC as exclusive sales agent and removes the limit on the amount of shares that can be sold under the agreement. 7. 2025-07-30 Financings [AIM ImmunoTech prices $8.0 million unit offering as it works to fix equity shortfall](https://aibio.space/news/aim-immunotech-prices-8-0-million-unit-offering-works-fix-equity/) AIM ImmunoTech sold units at $4.00 with two warrants each, a month after a 1-for-100 reverse split, and its prospectus says there is likely substantial doubt about its ability to continue as a going concern. It must lift stockholders' equity to at least $6 million by June 11, 2026. 8. 2025-06-20 Listings [AIM ImmunoTech gets new NYSE American notice over stockholders' deficit](https://aibio.space/news/aim-immunotech-gets-new-nyse-american-notice-stockholders-deficit/) AIM ImmunoTech had a stockholders' deficit of negative $3.9 million at March 31, 2025, and its 2024 net loss was approximately $17,320,000. Its tax-loss sales are capped, and the exchange deadline to fix the deficit is June 11, 2026. 9. 2025-06-12 Listings [AIM ImmunoTech regains NYSE American compliance as 1-for-100 reverse stock split takes effect](https://aibio.space/news/aim-immunotech-regains-nyse-american-compliance-1-100-reverse-stock/) AIM ImmunoTech regained NYSE American compliance on its low selling price test after a 1-for-100 reverse split effective June 12, 2025, with trading under AIM due to resume June 17. Its 2024 annual report carries a going-concern warning and a working capital deficit, and a separate stockholders' equity notice from December 2024 is not covered by this filing. 10. 2025-04-07 Listings [AIM ImmunoTech gets NYSE American delisting notice over low stock price](https://aibio.space/news/aim-immunotech-gets-nyse-american-delisting-notice-low-stock-price/) NYSE American suspended trading in AIM ImmunoTech (NYSE American: AIM) and began delisting proceedings, citing the low selling price of the stock. The company plans to appeal and expects Pink Open Market trading on April 7, 2025. ## AIM ImmunoTech at a glance - **Ticker**: AIM - **Listing**: AMEX - **Country**: United States - **Cash, Jun 30, 2026**: $10.0 million ### Related companies - [Aclaris Therapeutics](https://aibio.space/companies/aclaris-therapeutics/) NASDAQ: ACRS - [PTC Therapeutics](https://aibio.space/companies/ptc-therapeutics/) NASDAQ: PTCT - [Anebulo Pharmaceuticals](https://aibio.space/companies/anebulo-pharmaceuticals/) OTC: ANEB - [BlossomHill Therapeutics](https://aibio.space/companies/blossomhill-therapeutics/) NASDAQ: BLSM - [Retrieve Medical Holdings](https://aibio.space/companies/retrieve-medical/) OTC: RMHI - [AEON Biopharma](https://aibio.space/companies/aeon-biopharma/) AMEX: AEON - [Viatris](https://aibio.space/companies/viatris/) NASDAQ: VTRS - [Azitra](https://aibio.space/companies/azitra/) AMEX: AZTR ### Also on AMEX - [MAIA Biotechnology](https://aibio.space/companies/maia-biotechnology/) MAIA - [IGC Pharma](https://aibio.space/companies/igc-pharma/) IGC - [Actinium Pharmaceuticals, Inc. (Delaware)](https://aibio.space/companies/actinium-pharmaceuticals-delaware/) ATNM - [Apimeds Pharmaceuticals US](https://aibio.space/companies/apimeds-pharmaceuticals-us/) APUS - [Oragenics](https://aibio.space/companies/oragenics/) OGEN - [Cel-Sci](https://aibio.space/companies/cel-sci/) CVM ## What AIM ImmunoTech does AIM ImmunoTech Inc. is an immuno-pharma company headquartered in Ocala, Florida. It develops therapeutics for multiple types of cancers, viral diseases and immune-deficiency disorders. Its flagship product is Ampligen (rintatolimod), a double-stranded RNA molecule being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen has not been approved by the FDA or marketed in the United States, but it is approved for commercial sale in the Argentine Republic for severe Chronic Fatigue Syndrome. AIM has chosen to focus on late-stage pancreatic cancer. Its investigator-initiated Phase 2 DURIPANC study combines Ampligen with AstraZeneca's Imfinzi (durvalumab) in metastatic pancreatic cancer patients, with eighteen patients enrolled. In March 2026, AIM announced an agreement with the PPD clinical research business of Thermo Fisher Scientific to design an anticipated Phase 3 trial. Other programs cover antiviral uses, ME/CFS and Ampligen as a vaccine adjuvant with AstraZeneca's FluMist. The company also lists Alferon N Injection (Interferon alfa) among its products. | Product or program | What it is | Stage | |---|---|---| | Ampligen (rintatolimod) | Double-stranded RNA molecule for cancers, viral diseases and immune disorders | Approved for severe Chronic Fatigue Syndrome in Argentina; not approved by the FDA | | DURIPANC study (Ampligen with Imfinzi) | Combination for metastatic pancreatic cancer after FOLFIRINOX | Phase 2 | | Alferon N Injection | Interferon alfa product | | Summarised from the company's [10-K filed Mar 27, 2026](https://www.sec.gov/Archives/edgar/data/946644/000149315226013301/form10-k.htm). ## AIM ImmunoTech annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$88,000](https://www.sec.gov/Archives/edgar/data/946644/000149315226013301/) | [$170,000](https://www.sec.gov/Archives/edgar/data/946644/000149315226013301/) | | Research and development | [$3.9 million](https://www.sec.gov/Archives/edgar/data/946644/000149315226013301/) | [$6.2 million](https://www.sec.gov/Archives/edgar/data/946644/000149315226013301/) | | Net income (loss) | [-$14.0 million](https://www.sec.gov/Archives/edgar/data/946644/000149315226013301/) | [-$17.3 million](https://www.sec.gov/Archives/edgar/data/946644/000149315226013301/) | | Cash from operations | [-$11.0 million](https://www.sec.gov/Archives/edgar/data/946644/000149315226013301/) | [-$14.9 million](https://www.sec.gov/Archives/edgar/data/946644/000149315226013301/) | | Cash and equivalents | [$3.0 million](https://www.sec.gov/Archives/edgar/data/946644/000149315226036609/) | [$1.7 million](https://www.sec.gov/Archives/edgar/data/946644/000149315226013301/) | | Short-term investments | [$62,000](https://www.sec.gov/Archives/edgar/data/946644/000149315226036609/) | [$2.3 million](https://www.sec.gov/Archives/edgar/data/946644/000149315226013301/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $9.9 million, plus short-term investments of $64,000, $10.0 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about AIM ImmunoTech Did AIM ImmunoTech do a reverse stock split? Our latest story on this, dated Jul 30, 2025: "AIM ImmunoTech prices $8.0 million unit offering as it works to fix equity shortfall". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/aim-immunotech-prices-8-0-million-unit-offering-works-fix-equity/). Was AIM ImmunoTech delisted? Our latest story on this, dated Apr 7, 2025: "AIM ImmunoTech gets NYSE American delisting notice over low stock price". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/aim-immunotech-gets-nyse-american-delisting-notice-low-stock-price/). Has AIM ImmunoTech issued a going-concern warning? Our latest story on this, dated Jul 30, 2025: "AIM ImmunoTech prices $8.0 million unit offering as it works to fix equity shortfall". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/aim-immunotech-prices-8-0-million-unit-offering-works-fix-equity/). Has AIM ImmunoTech raised money recently? Our latest story on this, dated Apr 10, 2026: "AIM ImmunoTech amends at-the-market sales agreement with Maxim Group". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/aim-immunotech-amends-market-sales-agreement-maxim-group/). What is the ticker symbol of AIM ImmunoTech? AIM ImmunoTech Inc. trades under the ticker AIM on AMEX. Where is AIM ImmunoTech listed? AIM ImmunoTech Inc. is listed on AMEX. Our directory also records these other listings: LSE:0A4Y. What is the SEC CIK of AIM ImmunoTech? The SEC Central Index Key (CIK) for AIM ImmunoTech Inc. is 946644. Its filings are on SEC EDGAR. How many shares does AIM ImmunoTech have outstanding? 30,442,139 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-07. Which country or territory is AIM ImmunoTech listed under? Our directory records AIM ImmunoTech Inc. under United States. What does AIM ImmunoTech do? Our directory classifies AIM ImmunoTech Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of AIM ImmunoTech? The ISIN recorded for AIM ImmunoTech Inc. is US00901B3033. Does aibio.space cover AIM ImmunoTech? aibio.space lists AIM ImmunoTech Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is AIM ImmunoTech incorporated? SEC records list its state or country of incorporation as DE. What does AIM ImmunoTech develop? AIM ImmunoTech Inc. is an immuno-pharma company headquartered in Ocala, Florida. It develops therapeutics for multiple types of cancers, viral diseases and immune-deficiency disorders. What is Ampligen (rintatolimod) from AIM ImmunoTech? Ampligen (rintatolimod): Double-stranded RNA molecule for cancers, viral diseases and immune disorders Stage: Approved for severe Chronic Fatigue Syndrome in Argentina; not approved by the FDA. ## Investor discussion: AIM ImmunoTech Members talk about AIM ImmunoTech (AIM). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at AIM ImmunoTech, newest first. Each line links the filing it comes from. 1. 2026-09-04 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,1.02,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/946644/000149315226041537/form8-k.htm) 2. 2026-08-05 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/946644/000149315226036104/form8-k.htm) 3. 2026-07-16 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/946644/000149315226033514/form8-k.htm) 4. 2026-06-25 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/946644/000149315226030043/formdef14a.htm) 5. 2026-06-15 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/946644/000149315226028615/ex99-1.htm) 6. 2026-06-15 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/946644/000149315226028732/formpre14a.htm) 7. 2025-12-12 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/946644/000149315225027319/forms-1.htm) 8. 2025-11-17 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/946644/000149315225023724/formnt10-q.htm) 9. 2025-07-30 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/946644/000149315225011489/form424b5.htm) 10. 2025-06-20 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/946644/000164117225015861/ex99-1.htm) 11. 2025-06-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/946644/000164117225014899/ex99-1.htm) 12. 2025-05-01 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/946644/000164117225007954/form8-k.htm) 13. 2025-04-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/946644/000164117225002858/ex99-1.htm) 14. 2025-04-02 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/946644/000164117225002408/formdef14-a.htm) 15. 2025-04-01 Financings Reported a financing. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/946644/000164117225002131/forms-3.htm) 16. 2025-02-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/946644/000149315225008617/ex99-1.htm) 17. 2025-02-28 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/946644/000149315225008713/formpre14a.htm) 18. 2025-01-23 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/946644/000149315225003444/forms-1.htm) 19. 2024-12-17 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/946644/000149315224050433/ex99-1.htm) 20. 2024-11-14 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/946644/000149315224045971/form10-q.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open AMEX:AIM on TradingView](https://www.tradingview.com/symbols/AMEX-AIM/). ## SEC filings and registration - **SEC name**: AIM ImmunoTech Inc. - **CIK**: 946644 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: AIM (NYSE) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 2117 SW HIGHWAY 484, OCALA, FL, 32801 - **Phone**: 352-448-7797 - **Shares outstanding**: 30,442,139 as of 2026-08-07 (10-Q filed 2026-08-07) - **Former names**: AIM ImmunoTech Inc.; HEMISPHERX BIOPHARMA INC ### Recent filings (8-K and 6-K are the company's own announcements) - [DEF 14A](https://www.sec.gov/Archives/edgar/data/946644/000149315226045102/formdef14a.htm) filed 2026-09-30 - [8-K](https://www.sec.gov/Archives/edgar/data/946644/000149315226042592/form8-k.htm) filed 2026-09-14 - [8-K](https://www.sec.gov/Archives/edgar/data/946644/000149315226042196/form8-k.htm) filed 2026-09-10 - [8-K](https://www.sec.gov/Archives/edgar/data/946644/000149315226041537/form8-k.htm) filed 2026-09-04 - [8-K](https://www.sec.gov/Archives/edgar/data/946644/000149315226036996/form8-k.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/946644/000149315226036753/form8-k.htm) filed 2026-08-10 - [10-Q](https://www.sec.gov/Archives/edgar/data/946644/000149315226036609/form10-q.htm) filed 2026-08-07 - [8-K](https://www.sec.gov/Archives/edgar/data/946644/000149315226036408/form8-k.htm) filed 2026-08-06 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000946644), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details AIM ImmunoTech Inc. is a public biotech or pharmaceutical company listed on AMEX under the ticker AIM, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: AIM ImmunoTech Inc. - **Ticker**: AIM - **Listing**: AMEX - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US00901B3033 - **Other listed symbols**: LSE:0A4Y - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/AMEX-AIM/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/aim-immunotech/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "AIM ImmunoTech (AIM) news: reverse split and delisting", 2026-10-31, https://aibio.space/companies/aim-immunotech/